Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael R Kraus

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
Hepatology (Baltimore, Md.)|August 9, 2014
Reply: To PMID 23300053Arne Schäfer, Michael R Kraus, Michael Scheurlen
World Journal of Gastroenterology|March 29, 2005
Psychiatric side effects of pegylated interferon alfa-2b as compared to conventional interferon alfa-2b in patients with chronic hepatitis CMichael-R Kraus, Arne Schäfer, Herbert Csef, et al.
European Journal of Gastroenterology & Hepatology|November 18, 2005
Physician-patient relationship and disclosure behaviour in chronic hepatitis C in a group of German outpatientsArne Schäfer, Michael Scheurlen, Marc Felten, et al.
International Journal of Methods in Psychiatric Research|January 12, 2008
Methodological approaches in the assessment of interferon-alfa-induced depression in patients with chronic hepatitis C - a critical reviewArne Schäfer, Hans-Ulrich Wittchen, Jochen Seufert, et al.
Chemotherapy|May 15, 2007
Sustained virological response in the antiviral therapy of chronic hepatitis C: is there a predictive value of interferon-induced depression?Arne Schäfer, Michael Scheurlen, Benedikt Weissbrich, et al.
Clinical Pharmacology and Therapeutics|January 8, 2005
Neurocognitive changes in patients with hepatitis C receiving interferon alfa-2b and ribavirinMichael R Kraus, Arne Schäfer, Saskia Wissmann, et al.
Clinical and Diagnostic Laboratory Immunology|March 11, 2003
Nucleoporin p62 antibodies in a case of mixed connective tissue diseaseDoris M Kraemer, Michael R Kraus, Christian Kneitz, et al.
The Journal of Clinical Psychiatry|June 26, 2003
Psychiatric symptoms in patients with chronic hepatitis C receiving interferon alfa-2b therapyMichael R Kraus, Arne Schäfer, Hermann Faller, et al.
Infectious Diseases and Therapy|June 21, 2018
Clinical and Economic Burden of Hepatic and Extrahepatic Complications from Chronic Hepatitis C: A Retrospective Analysis of German Sickness Fund DataMichael R Kraus, Henning Kleine, Stefanie Thönnes, et al.
Infectious Diseases and Therapy|June 21, 2018
Improvement of Hepatic and Extrahepatic Complications from Chronic Hepatitis C After Antiviral Treatment: A Retrospective Analysis of German Sickness Fund DataMichael R Kraus, Henning Kleine, Stefanie Thönnes, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Hepatology (Baltimore, Md.)|August 9, 2014
Reply: To PMID 23300053Arne Schäfer, Michael R Kraus, Michael Scheurlen
World Journal of Gastroenterology|March 29, 2005
Psychiatric side effects of pegylated interferon alfa-2b as compared to conventional interferon alfa-2b in patients with chronic hepatitis CMichael-R Kraus, Arne Schäfer, Herbert Csef, et al.
European Journal of Gastroenterology & Hepatology|November 18, 2005
Physician-patient relationship and disclosure behaviour in chronic hepatitis C in a group of German outpatientsArne Schäfer, Michael Scheurlen, Marc Felten, et al.
International Journal of Methods in Psychiatric Research|January 12, 2008
Methodological approaches in the assessment of interferon-alfa-induced depression in patients with chronic hepatitis C - a critical reviewArne Schäfer, Hans-Ulrich Wittchen, Jochen Seufert, et al.
Chemotherapy|May 15, 2007
Sustained virological response in the antiviral therapy of chronic hepatitis C: is there a predictive value of interferon-induced depression?Arne Schäfer, Michael Scheurlen, Benedikt Weissbrich, et al.
Clinical Pharmacology and Therapeutics|January 8, 2005
Neurocognitive changes in patients with hepatitis C receiving interferon alfa-2b and ribavirinMichael R Kraus, Arne Schäfer, Saskia Wissmann, et al.
Clinical and Diagnostic Laboratory Immunology|March 11, 2003
Nucleoporin p62 antibodies in a case of mixed connective tissue diseaseDoris M Kraemer, Michael R Kraus, Christian Kneitz, et al.
The Journal of Clinical Psychiatry|June 26, 2003
Psychiatric symptoms in patients with chronic hepatitis C receiving interferon alfa-2b therapyMichael R Kraus, Arne Schäfer, Hermann Faller, et al.
Infectious Diseases and Therapy|June 21, 2018
Clinical and Economic Burden of Hepatic and Extrahepatic Complications from Chronic Hepatitis C: A Retrospective Analysis of German Sickness Fund DataMichael R Kraus, Henning Kleine, Stefanie Thönnes, et al.
Infectious Diseases and Therapy|June 21, 2018
Improvement of Hepatic and Extrahepatic Complications from Chronic Hepatitis C After Antiviral Treatment: A Retrospective Analysis of German Sickness Fund DataMichael R Kraus, Henning Kleine, Stefanie Thönnes, et al.
Pageof 3